Waters Corporation expected to boost growth in bioanalytical characterization for new modalities with acquisition of Wyatt Technology.
Waters Corporation has acquired Wyatt Technology, a specialist in light scattering instrumentation and software, which is expected to boost Waters’ growth in bioanalytical characterization for new modalities.
The acquisition, which was announced in a May 16, 2023 press release, will marry Wyatt’s analytical technologies with Waters’ global reach, to better serve the demands of the companies’ global customers. It is projected that revenue growth and margin profile for Waters will be positively impacted immediately, with estimates provided in the release that annual revenue growth worth more than $70 million will be seen by Waters within five years of the acquisition transaction being completed.
“We are pleased to complete the acquisition of Wyatt, which is a significant milestone for Waters as we advance our strategy to accelerate value creation and generate faster growth,” said Udit Batra, president and CEO, Waters Corporation. “With Wyatt, we are even better positioned to solve our customers’ critical challenges with differentiated bioanalytical characterization techniques. We welcome the Wyatt team to Waters and look forward to facilitating a smooth integration process and working together to deliver an unmatched set of bioanalytical characterization solutions to our global customers.”
Source: Waters
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.